Characterizing the efficacy of zuranolone across patient subgroups and symptom domains in Japanese patients with major depressive disorder: a pooled analysis of two placebo-controlled trials
AimZuranolone has been reported to reduce the 17-item Hamilton Rating Scale for Depression (HAM-D17) total score as early as Day 3 in Japanese patients with major depressive disorder (MDD), with the reduction in the HAM-D17 total score being maintained after the treatment period. This post hoc pooled analysis aimed to evaluate the treatment effects of zuranolone across baseline characteristics…
Read original article on Frontiers in Psychiatry | New and Recent Articles →Related news
-
Psychopathy is a key to integrating dimensional personality disorder constructs and psychotherapy: toward a reformulation of personality and its disruption
Switzerland
-
Repositioning community-based mental health care for people with psychosocial disabilities: a physical health equity–oriented whole-health recovery framework
Switzerland
-
Moral engine model: conceptualizing moral injury as a wound to the self caused by rupturing of defining and sustaining emotional attachments
Switzerland
-
Outcome indicators used in recovery college effectiveness studies: a scoping review
Switzerland
-
Altered gut microbiota and untargeted metabolomic features in patients with schizophrenia: a case–control study
Switzerland
-
Systematic review and meta-analysis on the efficacy and safety of combining repetitive transcranial magnetic stimulation with sertraline for adolescent depression in China
Switzerland
-
Psychotic symptom burden and serum uric acid as correlates in a limited-adjustment analysis of current suicidal ideation in schizophrenia: a cross-sectional study
Switzerland
-
Lived experiences of adolescent girls following child sexual abuse: disclosure, coping, and perceived school support
Switzerland